Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing drugs that restore or increase the effectiveness of existing antibiotics.
Synereca’s lead program is focused on developing an inhaled colistin and colistin potentiator therapeutic for the treatment of Multidrug Resistant (MDR) Gram negative ESKAPE pathogens. This combination product could expand the clinical utility of colistin for the treatment of serious and chronic lung infections in the face of antibiotic resistance.
In early 2017, the World Health Organization released a report identifying three classes of bacteria—Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacteriaceae family, which includes Klebsiella pneumoniae—for which it is a “Critical Priority” that effective antibiotics be discovered. Synereca’s discovery program has identified 7 chemical subclasses of compounds that potentiate the activity of the polymyxin class of antibiotics against multi-drug-resistant (MDR) Gram-negative bacteria, including those caused by the species outlined in the WHO report.
The company’s lead program focuses on compounds that potentiate the effectiveness of colistin (polymyxin E), the last line of defense against MDR Gram-negative bacterial infections, without increasing toxicity. The colistin potentiation program’s lead compounds shift the minimum inhibitory concentration (MIC) of colistin up to 4,000-fold in colistin-resistant isolates of K. pneumoniae, A. baumannii, and P. aeruginosa. Candidates have also demonstrated ability to reduce the protective dose (PD50) of colistin in an in vivo preclinical model of infection caused by a multi-drug resistant strain of A. baumannii.
Currently, the company is focusing on creating an inhaled combination product consisting of colistin and one of Synereca’s potentiator compounds. Initial efficacy studies using a murine K. pneumoniae respiratory infection model are ongoing, with early data showing that the combination of our lead compound plus colistin demonstrated a reduction in the lung bacterial burden compared to colistin alone.
“Initial research shows that a continued rise in resistance by 2050 would lead to 10 million people dying every year and cost the world up to 100 trillion USD.”Jim O'Neill